Patients save $500–$3,000/year — often much more on brand-name cardiac drugs.*
1Check First (5 min)
2Deeper Savings (15 min)
3If Still Too Expensive
Enter the name of the drug you need — brand name or generic.
Optional — leave blank to see general options
Stay Informed
We monitor manufacturer savings cards, TrumpRx additions, and major price changes so you don't have to. Plus: open enrollment reminders and a January deductible-reset alert.
Detailed savings breakdowns for the most frequently prescribed cardiac, metabolic, and blood pressure medications.
Eliquis
apixaban
View savings →
Xarelto
rivaroxaban
View savings →
Entresto
sacubitril/valsartan
View savings →
Jardiance
empagliflozin
View savings →
Repatha
evolocumab
View savings →
Farxiga
dapagliflozin
View savings →
Brilinta
ticagrelor
View savings →
Ozempic
semaglutide
View savings →
Wegovy
semaglutide 2.4 mg
View savings →
Multaq
dronedarone
View savings →
Atorvastatin
Lipitor generic
View savings →
Rosuvastatin
Crestor generic
View savings →
Metoprolol
Toprol-XL generic
View savings →
Lisinopril
Prinivil generic
View savings →
Amlodipine
Norvasc generic
View savings →
Clopidogrel
Plavix generic
View savings →
Trulicity
dulaglutide
View savings →
Praluent
alirocumab
View savings →
Zepbound
tirzepatide
View savings →
Victoza
liraglutide
View savings →
Mounjaro
tirzepatide
View savings →
All 8 categories of savings options — expand any section to see sources and direct links.
Important: Copay Cards Don't Work for Medicare/Medicaid
Manufacturer copay cards (Eliquis, Xarelto, Entresto, Jardiance, Farxiga, Brilinta, and others) are only available to patients with commercial insurance. Medicare and Medicaid patients should focus on Patient Assistance Programs, Medicare Extra Help, and International Pharmacies instead.
* How we calculated the savings estimate: The lower bound ($500/year) reflects average annual savings for patients using GoodRx discount cards on common generic medications, based on GoodRx's published data showing an average 82% savings off retail prices across ~25 million users (GoodRx, 2024). The upper bound ($3,000/year) reflects savings for patients on expensive brand-name cardiac medications (e.g., Xarelto 20mg or Eliquis 5mg) who switch from US retail pricing (~$500–$550/month) to verified international pharmacies (~$80–$130/month) via PharmacyChecker-accredited sources — a difference of approximately $1,500–$4,600/year. Patient Assistance Programs (PAPs) can yield even greater savings for eligible patients; a peer-reviewed study (PMC, 2022) found PAPs saved patients an average of $3,072/year at a single cancer center. Savings vary significantly by medication, insurance status, and program eligibility. These figures are illustrative estimates, not guarantees. GoodRx Impact Report · PharmacyChecker · PMC PAP Savings Study (2022)